PhuturdexDrug Pipeline Intelligence

Phuturdex › Drugs › WX390

Drugs in development · updated 30 October 2026

WX390: clinical trials and development status

Development codeNot approved in the USNo EMA authorisationEstimated launch Nov 2030 – Sep 2031 (Phuturdex estimate)

As of 30 October 2026 WX390 is in 4 active clinical trials (recruiting or ongoing, phases I–III) for 0 diseases. The most advanced phase is III.

4Active trials
IIIMost advanced phase
0Diseases studied

Summary updated every week · data as of 30 October 2026. In Phuturdex you can follow WX390 and get an email at every change or safety alert.

Sign in free →

Everything on WX390

In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.

Open in Phuturdex →

Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.

ItalianoFrançaisDeutsch